» Articles » PMID: 18164823

Involvement of Subthalamic Nucleus in the Stimulatory Effect of Delta(9)-tetrahydrocannabinol on Dopaminergic Neurons

Overview
Journal Neuroscience
Specialty Neurology
Date 2008 Jan 1
PMID 18164823
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The cannabinoid CB1 receptor which is densely located in the basal ganglia is known to participate in the regulation of movement. The present study sought to determine the mechanisms underlying the effect of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) on neurons in the substantia nigra pars compacta (SNpc) using single-unit extracellular recordings in anesthetized rats. Administration of Delta(9)-THC (0.25-2 mg/kg, i.v.) increased the firing rate of SNpc neurons (maximal effect: 33.54+/-6.90%, n=8) without modifying other firing parameters (coefficient of variation and burst firing). This effect was completely blocked by the cannabinoid receptor antagonist rimonabant (0.5 mg/kg, i.v.). In addition, the blockade of excitatory amino acids receptors by kynurenic acid (0.5 microM, i.c.v.) or a chemical lesion of the subthalamic nucleus (STN) with ibotenic acid abolished Delta(9)-THC effect. These results indicate that CB1 receptor activation modulates SNpc neuronal activity by an indirect mechanism involving excitatory amino acids, probably released from STN axon terminals in the SNpc.

Citing Articles

Levodopa-Induced Dyskinesias in Parkinson's Disease: An Overview on Pathophysiology, Clinical Manifestations, Therapy Management Strategies and Future Directions.

di Biase L, Pecoraro P, Carbone S, Caminiti M, Di Lazzaro V J Clin Med. 2023; 12(13).

PMID: 37445461 PMC: 10342913. DOI: 10.3390/jcm12134427.


Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems.

Fantegrossi W, Wilson C, Berquist M Drug Metab Rev. 2018; 50(1):65-73.

PMID: 29385930 PMC: 6419500. DOI: 10.1080/03602532.2018.1428343.


Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection.

More S, Choi D Mol Neurodegener. 2015; 10:17.

PMID: 25888232 PMC: 4404240. DOI: 10.1186/s13024-015-0012-0.


Behavioral and neurochemical changes in mesostriatal dopaminergic regions of the rat after chronic administration of the cannabinoid receptor agonist WIN55,212-2.

Fanarioti E, Mavrikaki M, Panagis G, Mitsacos A, Nomikos G, Giompres P Int J Neuropsychopharmacol. 2014; 18(6).

PMID: 25522428 PMC: 4438542. DOI: 10.1093/ijnp/pyu097.


The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats.

Aristieta A, Azkona G, Sagarduy A, Miguelez C, Ruiz-Ortega J, Sanchez-Pernaute R PLoS One. 2012; 7(8):e42652.

PMID: 22880070 PMC: 3412805. DOI: 10.1371/journal.pone.0042652.